Business
Esperion Announces Two NEXLETOL® (bempedoic acid) Data Presentations at the American College of Cardiology’s 71st Annual Scientific Session & Expo
New Analyses of thousands of patients spanning Phase 2 and pooled Phase 3 data demonstrate that NEXLETOL safely and significantly lowers LDL-C compared to
About this update from Esperion Therapeutics, Inc.
[{"type":"text","content":"New Analyses of thousands of patients spanning Phase 2 and pooled Phase 3 data demonstrate that NEXLETOL safely and significantly lowers LDL-C compared to placebo in patients with renal impairment or hypertension\nANN ARBOR, Mich., April 03, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL®) at the American College of Cardiology’s 71st Annual Scientific Session & Expo (ACC.22). The first analysis titled, “Safety and Efficacy of Bempedoic Acid in Patients with Renal Impairment,” was presented by Peter P. Toth, MD, PhD, FCCP, FAHA, FESC, FACC. This analysis of a total of 3,619 patients included in four Phase 3 studies demonstrated that bempedoic acid 180 mg significantly lowered low-density lipoprotein cholesterol (LDL-C) (p","length":1017,"tagName":"div"}]